focus
LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.
Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.
advertisement
The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
As demand for Covid shots wanes, Moderna seeks its next success
Next article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Tori Bowie and the unacceptable rates of Black maternal death
